Literature DB >> 25303140

Risk assessment of tuberculosis in immunocompromised patients. A TBNET study.

Martina Sester1, Frank van Leth, Judith Bruchfeld, Dragos Bumbacea, Daniela M Cirillo, Asli Gorek Dilektasli, José Domínguez, Raquel Duarte, Martin Ernst, Fusun Oner Eyuboglu, Irini Gerogianni, Enrico Girardi, Delia Goletti, Jean-Paul Janssens, Inger Julander, Berit Lange, Irene Latorre, Monica Losi, Roumiana Markova, Alberto Matteelli, Heather Milburn, Pernille Ravn, Theresia Scholman, Paola M Soccal, Marina Straub, Dirk Wagner, Timo Wolf, Aslihan Yalcin, Christoph Lange.   

Abstract

RATIONALE: In the absence of active tuberculosis, a positive tuberculin skin test (TST) or interferon-γ release assay (IGRA) result defines latent infection with Mycobacterium tuberculosis, although test results may vary depending on immunodeficiency.
OBJECTIVES: This study compared the performance of TST and IGRAs in five different groups of immunocompromised patients, and evaluated their ability to identify those at risk for development of tuberculosis.
METHODS: Immunocompromised patients with HIV infection, chronic renal failure, rheumatoid arthritis, solid-organ or stem-cell transplantation, and healthy control subjects were evaluated head-to-head by the TST, QuantiFERON-TB-Gold in-tube test (ELISA), and T-SPOT.TB test (enzyme-linked immunospot) at 17 centers in 11 European countries. Development of tuberculosis was assessed during follow-up.
MEASUREMENTS AND MAIN RESULTS: Frequencies of positive test results varied from 8.7 to 15.9% in HIV infection (n = 768), 25.3 to 30.6% in chronic renal failure (n = 270), 25.0% to 37.2% in rheumatoid arthritis (n = 199), 9.0 to 20.0% in solid-organ transplant recipients (n = 197), 0% to 5.8% in stem-cell transplant recipients (n = 103), and 11.2 to 15.2% in immunocompetent control subjects (n = 211). Eleven patients (10 with HIV infection and one solid-organ transplant recipient) developed tuberculosis during a median follow-up of 1.8 (interquartile range, 0.2-3.0) years. Six of the 11 patients had a negative or indeterminate test result in all three tests at the time of screening. Tuberculosis incidence was generally low, but higher in HIV-infected individuals with a positive TST (3.25 cases per 100 person-years) than with a positive ELISA (1.31 cases per 100 person-years) or enzyme-linked immunospot result (1.78 cases per 100 person-years). No cases of tuberculosis occurred in patients who received preventive chemotherapy.
CONCLUSIONS: Among immunocompromised patients evaluated in this study, progression toward tuberculosis was highest in HIV-infected individuals and was poorly predicted by TST or IGRAs. Clinical trial registered with www.clinicaltrials.gov (NCT 00707317).

Entities:  

Keywords:  TBNET; immunocompromised; interferon-γ release assays; tuberculin-skin test; tuberculosis

Mesh:

Year:  2014        PMID: 25303140     DOI: 10.1164/rccm.201405-0967OC

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  66 in total

Review 1.  Update in Mycobacterium tuberculosis lung disease 2014.

Authors:  Paul Elkington; Alimuddin Zumla
Journal:  Am J Respir Crit Care Med       Date:  2015-10-01       Impact factor: 21.405

2.  Calcineurin Inhibitors and Variation in the Performance of Interferon-γ Release Assays Used to Detect Tuberculosis Infection.

Authors:  Edward Barton; Yifang Gao; Darran Ball; Katy Fidler; Nigel Klein; Nigel Curtis; Vanessa Clifford; Ben G Marshall; Andrew Chancellor; Salah Mansour; Paul Elkington; Marc Tebruegge
Journal:  Ann Am Thorac Soc       Date:  2019-06

Review 3.  [Diagnostics and treatment of tuberculosis under immunotherapy for multiple sclerosis : Current status and recommendations in Germany].

Authors:  Stefan Bittner; Sinah Engel; Christoph Lange; Martin S Weber; Aiden Haghikia; Felix Luessi; Thomas Korn; Luisa Klotz; Antonios Bayas; Friedemann Paul; Christoph Heesen; Martin Stangel; Brigitte Wildemann; Florian Then Bergh; Björn Tackenberg; Corinna Trebst; Clemens Warnke; Ralf Linker; Martin Kerschensteiner; Uwe Zettl; Hayrettin Tumani; Wolfgang Brück; Sven G Meuth; Tanja Kümpfel; Bernhard Hemmer; Heinz Wiendl; Ralf Gold; Frauke Zipp
Journal:  Nervenarzt       Date:  2019-12       Impact factor: 1.214

4.  International Congress of Drug Therapy in HIV Infection 23-26 October 2016, Glasgow, UK.

Authors: 
Journal:  J Int AIDS Soc       Date:  2016-10-23       Impact factor: 5.396

5.  Comparative Evaluation of QuantiFERON-TB Gold In-Tube and QuantiFERON-TB Gold Plus in Diagnosis of Latent Tuberculosis Infection in Immunocompromised Patients.

Authors:  Mi Ra Ryu; Min-Seung Park; Eun Hye Cho; Chul Won Jung; Kihyun Kim; Seok Jin Kim; Ha Young Oh; Wooseong Huh; Hye Ryoun Jang; Won-Jung Koh; Hye Yun Park; Young-Ho Kim; Dong Hyun Sinn; Jin-Oh Choi; Jae-Won Joh; Jong Man Kim; Sung Joo Kim; Jae Berm Park; Eun-Suk Kang
Journal:  J Clin Microbiol       Date:  2018-10-25       Impact factor: 5.948

6.  Discovery and validation of a personalized risk predictor for incident tuberculosis in low transmission settings.

Authors:  Marc Lipman; Mahdad Noursadeghi; Ibrahim Abubakar; Rishi K Gupta; Claire J Calderwood; Alexei Yavlinsky; Maria Krutikov; Matteo Quartagno; Maximilian C Aichelburg; Neus Altet; Roland Diel; Claudia C Dobler; Jose Dominguez; Joseph S Doyle; Connie Erkens; Steffen Geis; Pranabashis Haldar; Anja M Hauri; Thomas Hermansen; James C Johnston; Christoph Lange; Berit Lange; Frank van Leth; Laura Muñoz; Christine Roder; Kamila Romanowski; David Roth; Martina Sester; Rosa Sloot; Giovanni Sotgiu; Gerrit Woltmann; Takashi Yoshiyama; Jean-Pierre Zellweger; Dominik Zenner; Robert W Aldridge; Andrew Copas; Molebogeng X Rangaka
Journal:  Nat Med       Date:  2020-10-19       Impact factor: 53.440

7.  IGRA testing in patients with immune-mediated inflammatory diseases: which factors influence the results?

Authors:  Juan González-Moreno; Mercedes García-Gasalla; Inés Losada-López; Carmen Cifuentes Luna; Isabel Mir Viladrich; Victoria Fernández-Baca; Araceli Serrano; Antonio Juan Mas; Joan Riera-Oliver; Antoni Payeras Cifre
Journal:  Rheumatol Int       Date:  2017-10-19       Impact factor: 2.631

8.  Structure-activity relationship studies on 2,5,6-trisubstituted benzimidazoles targeting Mtb-FtsZ as antitubercular agents.

Authors:  Krupanandan Haranahalli; Simon Tong; Saerom Kim; Monaf Awwa; Lei Chen; Susan E Knudson; Richard A Slayden; Eric Singleton; Riccardo Russo; Nancy Connell; Iwao Ojima
Journal:  RSC Med Chem       Date:  2020-10-16

9.  Immunodiagnostic Tests' Predictive Values for Progression to Tuberculosis in Transplant Recipients: A Prospective Cohort Study.

Authors:  Laura Muñoz; Aina Gomila; Susana Casas; José Castellote; Montserrat Arnan; Antoni Rafecas; Miguel Santin
Journal:  Transplant Direct       Date:  2015-04-01

10.  Risk of active tuberculosis in patients with inflammatory arthritis receiving TNF inhibitors: a look beyond the baseline tuberculosis screening protocol.

Authors:  Alina Soare; Ana Maria Gheorghiu; Victoria Aramă; Dragoș Bumbăcea; Rucsandra Dobrotă; Raida Oneaţă; Simona Pintilie; Mihaela Milicescu; Ioan Ancuţa; Andrei Martin; Mariana Sasu; Claudia Ciofu; Liviu Macovei; Victor Stoica; Mihai Bojincă; Carina Mihai
Journal:  Clin Rheumatol       Date:  2017-11-17       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.